[MO33] Mini-Oral Session 33　COVID-19 2

[MO33-6] Safety of anti SARS-CoV-2 Messenger RNA Vaccine for Patients with Advanced Lung Cancer Treated with Anti-cancer Drugs

^○Sayaka Tachibana¹, Koji Inoue¹, Tomoki Tamura², Kiichiro Ninomiya³, Toshio Kubo⁴, Shoichi Kuyama², Sayaka Tachibana¹, , Kenichi Chikamori⁵, Kenichiro Kudo⁶ , Nobuaki Ochi⁷, Daijiro Harada⁸, , Yoshinobu Maeda³, , Katsuyuki Kiura⁹ (1.Department of Respiratory Medicine, Ehime Prefectural Central Hospital, 2.Department of Respiratory Medicine, NHO Iwakuni Clinical Center, Iwakuni
3.Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 4. Center for Clinical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 5. Department of Medical Oncology, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, 6. Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center,Okayama, 7. General Internal Medicine 4, Kawasaki Medical School, Okayama, 8. Department of Thoracic Oncology, NHO Shikoku Cancer Center, Matsuyama, 9. Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama)